Opinion|Videos|January 14, 2025
Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up
Author(s)Max Kates, MD
Max Kates, MD, discusses how early complete response rates exceeding 50% at 3 months with newer therapies are encouraging, though long-term follow-up remains critical for evaluating durability of response and establishing real-world effectiveness compared with clinical trial outcomes.
Advertisement
Episodes in this series
- Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
- How do these clinical trial outcomes compare to what you see in your clinical practice when treating patients with newer therapies?
- Discuss the importance of long-term follow-up for patients receiving these newer treatments.
- What is your experience in terms of durability of response?
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5